オールトランスレチノイン酸 all-trans-retinoic acid
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/07/31 04:20:32」(JST)
Systematic (IUPAC) name | |
---|---|
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
|
|
Clinical data | |
Trade names | Avita, Renova, Retin-a |
AHFS/Drugs.com | monograph |
MedlinePlus | a682437 |
Licence data | US Daily Med:link |
Pregnancy category |
|
Legal status |
|
Routes of administration |
Topical, oral |
Pharmacokinetic data | |
Protein binding | > 95% |
Biological half-life | 0.5-2 hours |
Identifiers | |
CAS Registry Number | 302-79-4 N |
ATC code | D10AD01 L01XX14 |
PubChem | CID: 444795 |
IUPHAR/BPS | 2644 |
DrugBank | DB00755 Y |
ChemSpider | 392618 Y |
UNII | 5688UTC01R Y |
KEGG | D00094 Y |
ChEBI | CHEBI:15367 Y |
ChEMBL | CHEMBL38 Y |
Chemical data | |
Formula | C20H28O2 |
Molecular mass | 300.4412 g/mol |
SMILES
|
|
InChI
|
|
Physical data | |
Melting point | 180 °C (356 °F) |
N (what is this?) (verify) |
Tretinoin (etymology and pronunciation) is retinoic acid in pharmaceutical form. One of several retinoids, it is the carboxylic acid form of vitamin A and is also known as all-trans retinoic acid or ATRA. It is a first generation topical retinoid commonly used to treat acne vulgaris and keratosis pilaris. It is available as a cream or gel (brand names Aberela, Airol, A-Ret, Atralin, Avita, Retacnyl, Refissa, Renova, Retin-A, Retino-A, ReTrieve, or Stieva-A). The most common strengths are 0.025%, 0.05% and 0.1%. It is also used to treat acute promyelocytic leukemia (APL), and is sold for this indication by Roche under the brand name Vesanoid. It is also available as a generic. Its isomer, isotretinoin, is also an acne drug.
It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.[1]
Tretinoin was co-developed by James Fulton and Albert Kligman in 1969.[2] Together, Fulton and Kligman are credited as the inventors of Retin-A.[2] Fulton was a researcher at the University of Pennsylvania at the time.[2] The University of Pennsylvania held the patent for Retin-A, which it licensed to pharmaceutical companies.[2]
Tretinoin is most commonly used as a form of acne treatment.[3] It was the first retinoid developed for this type of topical use.[citation needed] Tretinoin is the best studied retinoid in the treatment of photoaging.[4] It is used by some as a hair loss treatment [5] and is a component of many commercial products that are advertised as being able to slow skin aging or remove wrinkles.[6][7] Topical tretinoin is also used to treat and reduce the appearance of stretch marks by increasing collagen production in the dermis.[8]
Tretinoin, marketed as Vesanoid, is used to treat at least one form of cancer (acute promyelocytic leukemia, also called acute myeloid leukemia subtype M3), usually together with other drugs, by causing the immature promyelocytes to differentiate (i.e. mature).[9][10]
The pathology of the leukemia is due to the highly proliferative immature cells; retinoic acid drives these cells to develop into functional cells, which helps to alleviate the disease.[citation needed] It is usually prescribed for 15 days every three months at about 8–10 10-mg capsules per day.[citation needed]
Successfully treating acute promyelocytic leukemia (APL) with Tretinoin was a major breakthrough in APL therapy.[11] It works in APL because the majority of cases involve a chromosomal translocation of chromosomes 15 and 17, which causes genetic fusion of the retinoic acid receptor (RAR) gene to the promyelocytic leukemia (PML) gene.[12] This fusion PML-RAR protein is responsible for preventing immature myeloid cells from differentiating into more mature cells. This block in differentiation is thought to cause leukemia. ATRA acts on PML-RAR to lift this block, causing the immature promyelocytes to differentiate to normal mature blood cells thus decreasing promyelocytes.[citation needed]
This section needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (December 2011) |
When used, dryness or increased sensitivity to sunlight of the affected skin may occur.[13] More sensitive patients may also experience redness, scaling, itching, and burning.[14] A gradual increase in the frequency and amount of tretinoin application is best, as this allows one's skin to adequately adjust to the drug. Patients should be careful to follow their physician's recommendations when beginning a round of treatment.
As this product may cause irritation, it may indirectly increase sun sensitivity and fragility of the skin.[15] Patients who are using the drug should apply moisturizer and sunscreen to reduce the chance of developing sunburn while using tretinoin.[15] Additionally, patients using tretinoin should be cautious when simultaneously using other topical medications that contain salicylic acid, resorcinol, or sulfur because these medications may potentiate the drying and possibly irritating effects of tretinoin.[16] Topical tretinoin should be avoided during pregnancy because its use has been linked to birth defects in several case reports.[17]
This section does not cite any references or sources. Please help improve this section by adding citations to reliable sources. Unsourced material may be challenged and removed. (December 2011) |
There is a unique complication of retinoic acid syndrome in patients with acute promyelocytic leukemia. This is associated with the development of dyspnea, fever, weight gain, peripheral edema and is treated with dexamethasone. The etiology of retinoic acid syndrome has been attributed to capillary leak syndrome from cytokine release from the differentiating promyelocytes.
It is a teratogen, and therefore can cause birth defects and tests have shown increases in fetal skull abnormalities in rats.[18] Women who are or may be pregnant, or who are seeking to become pregnant, are therefore warned against using it.[19] This teratogenic effect is caused by the interference of the exogenous retinoic acid with endogenous retinoic acid signaling, which plays a role in patterning the developing embryo. However the risks of topical tretinoin to the fetus seems to be limited.[20]
A study published by the European Respiratory Journal in 2002, suggested tretinoin can reverse the effects of emphysema in mice by returning elasticity (and regenerating lung tissue through gene mediation) to the alveoli.[21] Studies suggested this might form a promising treatment in human emphysema patients.[22] However, a newer follow-up study done in 2006 found inconclusive results ("no definitive clinical benefits") using vitamin A (retinoic acid) in treatment of emphysema in humans and stated further research is needed to reach conclusions on this treatment.[23]
The name tretinoin comes from trans- + retinoic,[24] and the name isotretinoin is the same root plus the prefix iso-. The following variants apply equally to both words. Given that retinoic is pronounced /ˌrɛtɨˈnoʊɨk/,[24][25][26][27] it is natural that /ˌtrɛtɨˈnoʊɨn/ is a commonly heard pronunciation. Dictionary transcriptions also include /ˌtrɨˈtɪnoʊ.ɨn/[25][26] and /ˈtrɛtɨnɔɪn/.[24][27]
|date=
(help)
|
|
|
|
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
リンク元 | 「急性白血病」「急性骨髄性白血病」「急性前骨髄球性白血病」「オールトランスレチノイン酸」「all-trans-retinoic acid」 |
関連記事 | 「AT」「ATR」 |
M0 | minimally differentiated acute myeloblastic leukemia | AML | ||
M1 | acute myeloblastic leukemia, without maturation | |||
M2 | acute myeloblastic leukemia, with granulocytic maturation | |||
M3 | promyelocytic, or acute promyelocytic leukemia | APL | ||
M4 | 急性骨髄単球性白血病 | acute myelomonocytic leukemia | AMMoL | |
M4eo | myelomonocytic together with bone marrow eosinophilia | |||
M5 | M5a | 急性単芽球性白血病 | acute monoblastic leukemia | AMoL |
M5b | 急性単球性白血病 | acute monocytic leukemia | ||
M6 | M6a | 赤白血病 | acute erythroid leukemias, including erythroleukemia | |
M6b | and very rare pure erythroid leukemia | |||
M7 | 急性巨核芽球性白血病 | acute megakaryoblastic leukemia | ||
M8 | 急性好塩基球性白血病 | acute basophilic leukemia | ||
L1 | 小細胞型 | |||
L2 | 大細胞型 | |||
L3 | Burkitt型 |
染色体核型 | 遺伝子異常 | |
予後良好群 | inv(16), t(8;21), t(15;17)(付加的染色体異常の有無を問わない) | 正常核型におけるNPM1のみの異常 |
中間群 | 正常核型, +8, t(9;11),その他の予後良好にも不良にも属さない染色体異常 | t(8;21), inv(16)患者におけるc-kit異常 |
予後不良群 | 複雑核型(3以上の異常), -5, -7, 5q-, 7q-,11q23異常(t(9;11)を除く), inv(3), t(3;3),t(6;9), t(9;22) | 正常核型におけるFLT3-ITDのみの異常 |
en
"acute myeloid leukemia" の検索結果 約 871,000 件中 1 - 100 件目 (0.27 秒) "acute myelogenous leukemia" の検索結果 約 2,130,000 件中 1 - 100 件目 (0.29 秒) "acute myelocytic leukemia" の検索結果 約 85,100 件中 1 - 100 件目 (0.44 秒)
jp
"acute myeloid leukemia" に一致する日本語のページ 約 36,400 件中 1 - 100 件目 (0.44 秒) "acute myelogenous leukemia" に一致する日本語のページ 約 2,920 件中 1 - 100 件目 (0.40 秒) "acute myelocytic leukemia" に一致する日本語のページ 約 417 件中 1 - 100 件目 (1.03 秒)
pubmed
"acute myeloid leukemia"Items 1 - 20 of 9850 "acute myelogenous leukemia"Items 1 - 20 of 4241 "acute myelocytic leukemia" Items 1 - 20 of 864
免疫組織化学 | 電子顕微鏡 | Auer小体 | 特徴 | |||||
MPO | α-naphtol acetate esterase | PAS | MPO | |||||
AML | 微分化型急性骨髄性白血病 | M0 | - | - | - | + | CD13, CD33が少なくとも一つ陽性。一見無顆粒 | |
未分化型急性骨髄芽球性白血病 | M1 | + | - | - | 1 | 芽球の3%以上MPO陰性、前骨髄球以降の分化無し | ||
分化型急性骨髄芽球性白血病 | M2 | + | - | - | 1 | 前骨髄球以降の分化 | ||
急性前骨髄球性白血病 | M3 | + | - | - | 多数 | 異型前骨髄球。ファゴット細胞陽性 | ||
骨髄単球性白血病 | M4 | + | + | - | (骨髄)>30%芽球、>20%単球系細胞 | |||
単球性白血病 | M5 | - | + | - | (骨髄)単芽球、前単球、単球>80% | |||
赤白血病 | M6 | - | - | - | (骨髄)>30%芽球、>50%赤芽球。グリコホリン陽性 | |||
巨核芽球性白血病 | M7 | - | - | - | + | CD41陽性, CD42陽性 | ||
ALL | - | - | + |
オールトランス型レチノイン酸 : 66 件 全トランス型レチノイン酸 : 約 55,700 件 オールトランスレチノイン酸 : 約 111,000 件 全トランスレチノイン酸 : 約 56,900 件
.